Engineering Artificial Antigen Presenting Cells for Efficient ...

More documents

Recommendations

Info

Polyclonal Replicative Potential ofAdult CD4 T Cells In VitroTotal Cells1E+201E+191E+181E+171E+161E+151E+141E+131E+121E+111E+101E+091E+081E+071E+06IL-2 Added Day 49No IL-2 Day 50Exponential growth (days) 60-100Mean log10 growth (fold) 9-12Mean Pop Doubling 30-400 10 20 30 40 50 60 70 80 90DayInteraction of LV-aAPC with CD8+ T Cell2 micronsCD8 TLV-aAPCSuhoski, M., Molecular Therapy 2007 May;15(5):981-8 2
Challenges of Treg Isolation,Expansion, and TestingTregs are uncommon: rigorous in vitro selection processis required.- What is the right balance between yield and purity?Tregs are hypoproliferative: ex vivo culture can select foreffector T cells-Rapamycin: friend to TregsPurity and potency-What % of FoxP3 expressing cells will be consideredenough for adoptive T cell therapy?Establishing the best aAPC to expand human PB and UCBTregs: Cell based aAPCs are superior to beads in expandingfunctional T reg cellsAdult Peripheral Blood Cord BloodCD25Adult CD25+ SelectedCord CD25 SelectedGodfrey, W. R. et al.Blood 105:750-758, 2005CD43
Page 1: Engineering Artificial Antigen Pres
Page 5 and 6: Treg Expansion with aAPCCD4+25+127-
Page 7 and 8: Closed System Production of MCB and
Page 9 and 10: In Vitro Suppression Assay:Day 17 K
Page 11: PENN - TRP• Tatiana Golovina• S

Engineering Artificial Antigen Presenting Cells for Efficient ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?